Adivo Founder to speak on how a human health discovery technology created significant additional value in animal health

Interested to learn more about how human drug discovery technologies can be adapted to realise early value in animal health? Come and listen to the story behind MorphoSys’ animal health spin-out, adivo, and its successful sale to Zoetis, the largest animal health company. Dr. Kathrin Ladetzki-Baehs began her career at MorphoSys, where she served in multiple roles within the R&D organization and ultimately as Director in Alliance Management, shepherding partnerships, and therapeutic projects in collaboration with international pharma partners. In 2018, she co-founded adivo GmbH, a MorphoSys spinout, alongside Dr. Markus Waldhuber, securing seed financing from High-Tech Gründerfonds, Occident and MorphoSys to develop CEASAR and FELIX, the first phage-display antibody libraries tailored for dogs and cats. After growing the team to around 25 scientists and establishing a promising pipeline in oncology and inflammatory diseases, adivo was acquired by Zoetis in September 2023, with its Puchheim labs becoming one of Zoetis’ innovation hubs for veterinary antibody discovery. Dr Ladetzki-Baehs will speak on the strategic thinking which led to the (initially human) phage display platform at MorphoSys being thought of as relevant to animal health and thence to adivo’s creation.